Dioctyl but-2-enedioate;ethenyl acetate | 26061-64-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Dioctyl but-2-enedioate;ethenyl acetate
• CAS: 26061-64-3
• 化学式: C24H42O6
• 分子量: 426.6
• InChiKey: WVSACHQXRPZHLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.04
• 重原子数：
  30
• 可旋转键数：
  20
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  78.9
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Bioadhesive compositions comprising hydrophobic polymers
  申请人：First Water Limited

  公开号：EP1559437A2

  公开（公告）日：2005-08-03

  Bioadhesive compositions which comprise a hydrophobic polymer wherein the concentration of the polymer at the surface of the adhesive is greater than its concentration in the bulk of the adhesive are described; and biomedical electrodes, fixation products and wound dressing containing them.

  描述了由疏水性聚合物组成的生物粘合剂组合物，其中聚合物在粘合剂表面的浓度高于其在粘合剂主体中的浓度；以及含有这些组合物的生物医学电极、固定产品和伤口敷料。
• Bioadhesive compositions and biomedical electrodes containing them
  申请人：——

  公开号：US20020035320A1

  公开（公告）日：2002-03-21

  Bioadhesive Compositions which comprise a hydrophobic polymer wherein the concentration of the polymer at the surface of the adhesive is greater than its concentration in the bulk of the adhesive are described; and biomedical electrodes, fixation products and wound dressings containing them.

  描述了由疏水性聚合物组成的生物粘合剂组合物，其中聚合物在粘合剂表面的浓度高于其在粘合剂主体中的浓度；以及含有这些组合物的生物医学电极、固定产品和伤口敷料。
• Bioadhesive compositions and wound dressings containing them
  申请人：——

  公开号：US20020037270A1

  公开（公告）日：2002-03-28

  A method for the treatment and/or prophylaxis of conditions characterized by overstimulation of the tachykinin receptors, which method comprises the administration to a mammal in need thereof of an effective, non-toxic, pharmaceutically acceptable amount of a compound of formula (I), or a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable salt thereof, wherein: Ar is an optionally substituted phenyl, naphthyl or C 5-7 cycloalkdienyl group, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four heteroatoms in the or each ring selected from S, O, N; R is linear or branched C 1-8 alkyl, C 3-7 cycloalkyl, C 4-7 cycloalkylalkyl, optionally substituted phenyl or phenyl C 1-6 alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatoms selected from O and N, hydroxy C 1-6 alkyl, amino C 1-6 alkyl, C 1-6 alkylaminoalkyl, di C 1-6 alkylaminoalkyl, C 1-6 acylaminoalkkyl, C 1-6 alkoxyalkyl, C 1-6 alkylcarbonyl, carboxy, C 1-6 alkoxycarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkyl, aminocarbonyl, C 1-6 alkylaminocarbonyl, di C 1-6 alkylaminocarbonyl, halogeno C 1-6 alkyl; or is a group —(CH 2) p— when cyclized onto Ar, where p is 2 or 3. R1 and R2, which may be the same or different, are independently hydrogen or C 1-6 linear or branched alkyl, or together form a —(CH2)n— group in which n represents 3, 4 or 5; or R 1 together with R forms a group —(CH 2)q—, in which q is 2, 3, 4 or 5; R 3 and R 4, which may be the same or different, are independently hydrogen, C 1-6 linear or branched alkyl, C 1-6 alkenyl, aryl, C 1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C 1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino, mono- and di-C 1-6 alkylamino, —O(CH 2)r—NT 2, in which r is 2, 3 or 4 and T is hydrogen or C 1-6 alkyl or it forms with the adjacent nitrogen a group (a) or (b), in which V and V 1 are independently hydrogen or oxygen and u is 0, 1 or 2; —O(CH 2 ) s—OW in which s is 2, 3 or 4 and W is hydrogen or C 1-6 alkyl; hydroxyalkyl, aminoalkyl, mono- or di-alkylaminoalkyl, alkylamino, alkylsulphonylamino, aminoacylamino, mono- or di-alkylaminoacylamino; with up to four R 3 substituents being present in the quinoline nucleus; or R 4 is a group —(CH 2 ) t — when cyclized onto R 5 as aryl, in which t is 1, 2 or 3; R 5 is branched or linear C 1-6 alkyl, C 3-7 cycloalkyl, C 4-7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four heteroatoms in the or each ring selected from S, O, N; X is O, S, or N-CaN.

  一种治疗和/或预防以速激肽受体过度刺激为特征的疾病的方法，该方法包括向有需要的哺乳动物施用有效、无毒、药学上可接受量的式(I)化合物或其药学上可接受的溶液或其药学上可接受的盐，其中：Ar 是任选取代的苯基、萘基或 C 5-7 环烷二烯基，或任选取代的单环或融合环杂环基团，具有芳香性质，含有 5 至 12 个环原子，在环中或每个环中包含最多四个选自 S、O、N 的杂原子；R 是线性或支链 C 1-8 烷基、C 3-7 环烷基、C 4-7 环烷基烷基、任选取代的苯基或苯基 C 1-6 烷基、任选取代的五元杂芳香环（最多包含四个选自 O 和 N 的杂原子）、羟基 C 1-6 烷基、氨基 C 1-6 烷基、C 1-6 烷基氨基烷基、二 C 1-6 烷基氨基烷基、C 1-6 氨基酰基、C 1-6 烷氧基烷基、C 1-6 烷基羰基、羧基、C 1-6 烷氧基羰基、C 1-6 烷基、氨基羰基、C 1-6 烷基氨基羰基、二 C 1-6 烷基氨基羰基、卤代 C 1-6 烷基；或环化到 Ar 上的基团-(CH 2) p-，其中 p 为 2 或 3。R1 和 R2 可以相同或不同，独立地为氢或 C 1-6 直链或支链烷基，或共同形成-(CH2)n-基团，其中 n 代表 3、4 或 5；或 R 1 与 R 共同形成-( )q-基团，其中 q 代表 2、3、4 或 5；R 3 和 R 4（可以相同或不同）独立地为氢、C 1-6 直链或支链烷基、C 1-6 烯基、芳基、C 1-6 烷氧基、羟基、卤素、硝基、氰基、羧基、羧酰胺基、磺酰胺基、C 1-6 烷氧基羰基、三氟甲基、酰氧基、酞酰亚胺基、氨基、单氨基或双氨基、邻苯二甲酰亚胺基、氨基、单-和双-C 1-6 烷基氨基、-O(CH 2)r-NT 2（其中 r 为 2、3 或 4，T 为氢或 C 1-6 烷基）或与相邻的氮形成基团 (a) 或 (b)，其中 V 和 V 1 独立地为氢或氧，u 为 0、1 或 2；-O(CH 2 ) s-OW，其中 s 为 2、3 或 4，W 为氢或 C 1-6 烷基；羟基烷基、氨基烷基、单-或二-烷基氨基烷基、烷基氨基、烷基磺酰基氨基、氨基酰基氨基、单-或二-烷基氨基酰基氨基；喹啉核中最多有四个 R 3 取代基；或 R 4 环化到 R 5 上成为芳基时为基团-(CH 2 ) t-，其中 t 为 1、2 或 3；R 5 是支链或直链的 C 1-6 烷基、C 3-7 环烷基、C 4-7 环烷基烷基、任选取代的芳基或任选取代的单环或融合环杂环基团，具有芳香特性，含有 5 至 12 个环原子，在环中或每个环中包含最多 4 个杂原子，杂原子选自 S、O、N；X 是 O、S 或 N-CaN。
• BIOADHESIVE COMPOSITIONS AND WOUND DRESSINGS CONTAINING THEM
  申请人：First Water Limited

  公开号：EP1100555A1

  公开（公告）日：2001-05-23
• BIOADHESIVE COMPOSITIONS AND BIOMEDICAL ELECTRODES CONTAINING THEM
  申请人：First Water Limited

  公开号：EP1100556B1

  公开（公告）日：2003-11-12